Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 6/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8256333 | 1.00 | AKR1C3 (0.48) | AKR1C3KDM1ADRD3DRD2TSHR | |
| SCHEMBL25195403 | 0.90 | AKR1C3 (0.44) | AKR1C3KDM1ADRD3DRD2TSHR | |
| SCHEMBL8254274 | 0.81 | KDM1A (0.48) | AKR1C3KDM1ADRD3DRD2TSHR | |
| SCHEMBL8255283 | 0.81 | KDM1A (0.48) | AKR1C3KDM1ADRD3DRD2TSHR | |
| SCHEMBL12052350 | 0.81 | KDM1A (0.48) | AKR1C3KDM1ADRD3DRD2TSHR | |
| SCHEMBL803351 | 0.81 | ALOX5 (0.36) | AKR1C3HSD11B1ALDH1A1MAPT | |
| SCHEMBL803409 | 0.81 | ALOX5 (0.36) | AKR1C3HSD11B1ALDH1A1MAPT | |
| SCHEMBL802978 | 0.81 | ALOX5 (0.36) | AKR1C3HSD11B1ALDH1A1MAPT | |
| SCHEMBL8075166 | 0.78 | DRD3 (0.46) | KDM1ADRD3DRD2ALDH1A1HSD17B3 | |
| SCHEMBL8554662 | 0.78 | HTR1D (0.46) | AKR1C3KDM1ADRD3DRD2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835441-B2 | Heterobicyclic metalloprotease inhibitors | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | AKR1C3 2082/4885KDM1A 2074/4885DRD3 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.